The potential relationship between GLP-1 receptor agonists like semaglutide and thyroid C-cell tumors has been observed in rodent studies, where dose-dependent and duration-dependent increases in thyroid C-cell tumors were noted
Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in WEGOVY injection-treated adult patients compared to placebo in clinical trials for weight reduction
While many people may tolerate both semaglutide and Nyquil without major issues, the combination can lead to unwanted side effects for some
This decision allows the case to proceed into discovery, pretrial motions, and potential settlement discussions
The difference lies in the active peptide
Concerns about risks, especially diabetic ketoacidosis, and lack of data have prevented these medications from gaining approval in type 1 diabetes